Navigation Links
CVT Announces That FDA Continues to Review Ranexa(R) Applications
Date:7/28/2008

--FDA to provide draft labeling in the next few weeks--

PALO ALTO, Calif., July 28 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that it has been informed by the U.S. Food and Drug Administration (FDA) that it is continuing its review of CV Therapeutics' pending applications for Ranexa(R) (ranolazine extended-release tablets) past the Prescription Drug User Fee Act (PDUFA) action date of July 27, 2008. The applications seek a first line angina indication and promotable claims for the reduction of hemoglobin A1c (HbA1c) and ventricular arrhythmias in patients with coronary artery disease. The FDA has informed CV Therapeutics that the Company should receive draft labeling in the next few weeks, and the Company plans to promptly communicate when the labeling is complete.

On September 27, 2007, the Company announced it had submitted a supplemental new drug application (sNDA) to the FDA seeking an expansion of the approved product labeling for Ranexa. The submitted sNDA requested a new indication for first line treatment of chronic angina and a significant reduction in cautionary language, based on substantial data from the MERLIN TIMI-36 study.

In accordance with a special protocol assessment agreement between the FDA and CV Therapeutics, the Company believes that data from the MERLIN TIMI-36 study could support expansion of the existing Ranexa indication to first line angina.

Following submission of the initial sNDA, the FDA initiated a separate sNDA review by the Division of Cardiovascular and Renal Products to evaluate the approval of potential anti-arrhythmic claims and a separate new drug application review by the Division of Metabolism and Endocrinology Products to evaluate the approval of potential HbA1c reduction claims in patients with coronary artery disease.

Ranexa is currently indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Ltd. is the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Brookdale Announces Second Quarter 2008 Release and Earnings Call
2. Grupo Casa Saba Announces Sales and Operating Income Increased 14.05% and 13.45%, Respectively
3. Psychemedics Corporation Announces Second Quarter Results
4. American Heart Association CEO Announces Retirement
5. Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options
6. Dataline Announces Participation in Operation Golden Phoenix
7. Hoag Hospital Announces Agreement to Open Irvine Campus
8. ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call
9. The Connecticut Hospice, Inc. Announces the Arrival of Six Nurse Scholars From The Henrietta Szold-Hadassah-Hebrew University School of Nursing
10. ThermoGenesis Announces 10 New BioArchive(R) System Distributors
11. Tepha Announces Appointment of John Hartnett as Executive Vice President and Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... Brookfield, WI-based RF ... hospitality and education, is celebrating its 30th year in business this month. , ... manufacturing companies Square D, Allis Chalmers and Johnson Controls. Following his years in ...
(Date:8/17/2017)... ... August 17, 2017 , ... Recently ... once more by being among Houston’s first plastic surgeons to offer boutique and ... surgery care without disrupting busy schedules and maintaining the utmost discretion in the ...
(Date:8/17/2017)... Angeles, CA (PRWEB) , ... August 17, 2017 , ... ... partners Mark Hardiman, John Mills and Harry Nelson. This is the third consecutive year ... for Nelson. Hardiman and Nelson were both recognized for expertise in Health Care Law ...
(Date:8/17/2017)... ... August 17, 2017 , ... Tanya Atagi, MD, is excited ... CO, at Atagi Plastic Surgery and Skin Aesthetics. , To tighten skin on ... radiofrequency and ultrasound energy. Smoother, younger-looking skin is revealed on all other areas of ...
(Date:8/17/2017)... ... 17, 2017 , ... Dr. Charles W. Grimsley’s new book ... paperback, 9781498497626; $7.99, eBook, 9781498497633) focuses on the treatment of veterans diagnosed with ... forgiveness, through a progressive journey toward healing. This book will help readers learn ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... FLINT, Mich. , July 31, 2017  Diplomat Pharmacy, ... companies in southeast Michigan by ... feature ranks private and public companies by three-year revenue growth. ... To view the complete list, ... Crain,s Fast 50 is an incredible triumph," said Phil ...
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... July 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... for the second-quarter 2017 and updated financial guidance for ... Second-Quarter 2017 Highlights Reported net sales ... the prior-year quarter. Net sales at constant currency (organic) ... EPS was $0.51, compared to $0.60 in the prior-year ...
Breaking Medicine Technology: